JP2002527052A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002527052A5 JP2002527052A5 JP2000575546A JP2000575546A JP2002527052A5 JP 2002527052 A5 JP2002527052 A5 JP 2002527052A5 JP 2000575546 A JP2000575546 A JP 2000575546A JP 2000575546 A JP2000575546 A JP 2000575546A JP 2002527052 A5 JP2002527052 A5 JP 2002527052A5
- Authority
- JP
- Japan
- Prior art keywords
- leptin
- amino acid
- amino acids
- bioconjugate
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000001014 amino acid Nutrition 0.000 description 17
- 150000001413 amino acids Chemical group 0.000 description 14
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 13
- 102000016267 Leptin Human genes 0.000 description 10
- 108010092277 Leptin Proteins 0.000 description 10
- 239000004698 Polyethylene Substances 0.000 description 9
- -1 polyethylene Polymers 0.000 description 9
- 229920000573 polyethylene Polymers 0.000 description 9
- 125000003275 alpha amino acid group Chemical group 0.000 description 8
- 229940039781 leptin Drugs 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 4
- 125000003827 glycol group Chemical group 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 230000000536 complexating effect Effects 0.000 description 2
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/172,644 US6420339B1 (en) | 1998-10-14 | 1998-10-14 | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility |
| US09/172,644 | 1998-10-14 | ||
| PCT/US1999/024401 WO2000021574A2 (en) | 1998-10-14 | 1999-10-13 | Site-directed dual pegylation of proteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002527052A JP2002527052A (ja) | 2002-08-27 |
| JP2002527052A5 true JP2002527052A5 (https=) | 2006-11-30 |
| JP4854851B2 JP4854851B2 (ja) | 2012-01-18 |
Family
ID=22628578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000575546A Expired - Lifetime JP4854851B2 (ja) | 1998-10-14 | 1999-10-13 | 改善された生物活性と生体適合性のためのタンパク質の部位特異的二重ポリエチレングリコール化 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6420339B1 (https=) |
| EP (1) | EP1121155B1 (https=) |
| JP (1) | JP4854851B2 (https=) |
| AT (1) | ATE463260T1 (https=) |
| AU (1) | AU757860B2 (https=) |
| CA (1) | CA2345027C (https=) |
| DE (1) | DE69942231D1 (https=) |
| WO (1) | WO2000021574A2 (https=) |
Families Citing this family (112)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6841617B2 (en) | 2000-09-28 | 2005-01-11 | Battelle Memorial Institute | Thermogelling biodegradable aqueous polymer solution |
| US7087244B2 (en) | 2000-09-28 | 2006-08-08 | Battelle Memorial Institute | Thermogelling oligopeptide polymers |
| ES2257287T3 (es) * | 1999-02-12 | 2006-08-01 | Amgen Inc. | Composiciones de leptina glicosiladas y metodos relacionados. |
| US8106098B2 (en) | 1999-08-09 | 2012-01-31 | The General Hospital Corporation | Protein conjugates with a water-soluble biocompatible, biodegradable polymer |
| US6646110B2 (en) * | 2000-01-10 | 2003-11-11 | Maxygen Holdings Ltd. | G-CSF polypeptides and conjugates |
| US6831158B2 (en) * | 2000-01-10 | 2004-12-14 | Maxygen Holdings Ltd. | G-CSF conjugates |
| US6555660B2 (en) * | 2000-01-10 | 2003-04-29 | Maxygen Holdings Ltd. | G-CSF conjugates |
| KR100401296B1 (ko) * | 2000-12-27 | 2003-10-11 | 드림바이오젠 주식회사 | 수식물질에 의해 수식된 단백질 변이체 및 이것의 제조방법 |
| EP1234583A1 (en) * | 2001-02-23 | 2002-08-28 | F. Hoffmann-La Roche Ag | PEG-conjugates of HGF-NK4 |
| PL371781A1 (en) * | 2001-07-11 | 2005-06-27 | Maxygen Holdings, Ltd. | G-csf conjugates |
| AU2003228808A1 (en) * | 2002-05-02 | 2003-11-17 | Regents Of The University Of Minnesota | Fibrin-based biomatrix |
| WO2003094965A2 (en) * | 2002-05-08 | 2003-11-20 | Neuronova Ab | Modulation of neural stem cells with s1p or lpa receptor agonists |
| EP1837031B1 (en) * | 2002-06-07 | 2009-10-14 | Waratah Pharmaceuticals, Inc. | Compositions and methods for treating diabetes |
| ES2532399T3 (es) * | 2003-03-05 | 2015-03-26 | Halozyme, Inc. | Glicoproteína hialuronidasa soluble (sHASEGP), proceso para prepararla, usos y composiciones farmacéuticas que la comprenden |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| US20090123367A1 (en) * | 2003-03-05 | 2009-05-14 | Delfmems | Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases |
| EP1610825A2 (en) * | 2003-03-31 | 2006-01-04 | Xencor, Inc. | Methods for rational pegylation of proteins |
| US7642340B2 (en) | 2003-03-31 | 2010-01-05 | Xencor, Inc. | PEGylated TNF-α variant proteins |
| US7610156B2 (en) | 2003-03-31 | 2009-10-27 | Xencor, Inc. | Methods for rational pegylation of proteins |
| WO2005025553A2 (en) * | 2003-09-12 | 2005-03-24 | Neuronova Ab | Treatment of disorders of nervous systemsystem with fty720 |
| EP1675871A2 (en) | 2003-10-10 | 2006-07-05 | Xencor Inc. | Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders |
| US20060122784A1 (en) * | 2004-12-03 | 2006-06-08 | Ishikawa Muriel Y | System and method for augmenting a humoral immune response |
| EP2327724A3 (en) * | 2004-02-02 | 2011-07-27 | Ambrx, Inc. | Modified human growth hormone polypeptides and their uses |
| JP2007530569A (ja) * | 2004-03-23 | 2007-11-01 | アムジエン・インコーポレーテツド | 化学修飾タンパク質組成物及び方法 |
| KR101699142B1 (ko) * | 2004-06-18 | 2017-01-23 | 암브룩스, 인코포레이티드 | 신규 항원-결합 폴리펩티드 및 이의 용도 |
| JP2008507280A (ja) * | 2004-07-21 | 2008-03-13 | アンブレツクス・インコーポレイテツド | 非天然コードアミノ酸を用いた生合成ポリペプチド |
| US7816320B2 (en) | 2004-12-22 | 2010-10-19 | Ambrx, Inc. | Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35 |
| JP2008525473A (ja) | 2004-12-22 | 2008-07-17 | アンブレツクス・インコーポレイテツド | 修飾されたヒト成長ホルモン |
| GB2438760A (en) | 2004-12-22 | 2007-12-05 | Ambrx Inc | Methods for expression and purification of recombinant human growth hormone |
| CN102732588B (zh) | 2004-12-22 | 2015-01-07 | Ambrx公司 | 氨酰基-tRNA合成酶的组合物及其用途 |
| WO2006094530A1 (en) * | 2005-03-11 | 2006-09-14 | Siegfried Ltd. | Di-polymer protein conjugates and processes for their preparation |
| EP1888119B1 (en) * | 2005-06-01 | 2011-03-09 | Maxygen, Inc. | Pegylated g-csf polypeptides and methods of producing same |
| WO2006133089A2 (en) | 2005-06-03 | 2006-12-14 | Ambrx, Inc. | Improved human interferon molecules and their uses |
| US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
| MX2008002149A (es) | 2005-08-18 | 2008-04-22 | Ambrx Inc | Composiciones de arnt y sus usos. |
| EP1951890A4 (en) | 2005-11-16 | 2009-06-24 | Ambrx Inc | PROCESSES AND COMPOSITIONS WITH NON-NATURAL AMINO ACIDS |
| EP1834963A1 (en) * | 2006-03-13 | 2007-09-19 | Siegfried Ltd. | Di-polymer protein conjugates and processes for their preparation |
| CN106008699A (zh) * | 2006-09-08 | 2016-10-12 | Ambrx公司 | 经修饰的人类血浆多肽或Fc骨架和其用途 |
| MX2009002460A (es) | 2006-09-08 | 2009-03-20 | Ambrx Inc | Arnt supresor hibrido para celulas de vertebrados. |
| EP2064333B1 (en) | 2006-09-08 | 2014-02-26 | Ambrx, Inc. | Suppressor trna transcription in vertebrate cells |
| CA2682147C (en) | 2007-03-30 | 2017-08-08 | Ambrx, Inc. | Modified fgf-21 polypeptides and their uses |
| MX2009011870A (es) | 2007-05-02 | 2009-11-12 | Ambrx Inc | Polipeptidos de interferon beta modificados y usos de los mismos. |
| MX2010005317A (es) | 2007-11-20 | 2010-06-02 | Ambrx Inc | Polipeptidos de insulina modificados y sus usos. |
| NZ586947A (en) | 2008-02-08 | 2012-11-30 | Ambrx Inc | Modified leptin polypeptides and their uses |
| TWI395593B (zh) | 2008-03-06 | 2013-05-11 | Halozyme Inc | 可活化的基質降解酵素之活體內暫時性控制 |
| AR071169A1 (es) | 2008-03-31 | 2010-06-02 | Council Scient Ind Res | Variantes de la estreptoquinasa que contienen cisteina y sus formas covalentemente modificadas |
| KR20100135291A (ko) | 2008-04-14 | 2010-12-24 | 할로자임, 아이엔씨 | 히알루로난 관련 질환 및 상태 치료용 변형된 히알루로니다제 및 그 용도 |
| TWI394580B (zh) | 2008-04-28 | 2013-05-01 | Halozyme Inc | 超快起作用胰島素組成物 |
| WO2009149379A2 (en) * | 2008-06-05 | 2009-12-10 | Regents Of The University Of Michigan | Use of leptin for the treatment of fatty liver diseases and conditions |
| PT2318029T (pt) | 2008-07-23 | 2018-01-10 | Ambrx Inc | Polipéptidos de g-csf bovino modificados e suas utilizações |
| MX2011003272A (es) | 2008-09-26 | 2011-04-28 | Ambrx Inc | Polipeptidos de eritropoyetina animal modificados y sus usos. |
| PE20110480A1 (es) | 2008-09-26 | 2011-07-01 | Ambrx Inc | Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales |
| SG171957A1 (en) * | 2008-11-04 | 2011-07-28 | Janssen Pharmaceutica Nv | Crhr2 peptide agonists and uses thereof |
| CN103205407B (zh) | 2008-12-09 | 2016-03-16 | 哈洛齐梅公司 | 延长的可溶性ph20多肽及其用途 |
| CN102869384B (zh) | 2009-06-22 | 2016-01-13 | 伯纳姆医学研究所 | 使用带有c-端元件的肽和蛋白质的方法和组合物 |
| MX2012003282A (es) | 2009-09-17 | 2012-04-30 | Baxter Healthcare Sa | Co-formulacion estable de hialuronidasa e inmunoglobulina, y metodos de su uso. |
| US20110105397A1 (en) | 2009-11-04 | 2011-05-05 | Gengo Peter J | Method for treating heart failure with stresscopin-like peptides |
| NZ600361A (en) | 2009-12-21 | 2014-06-27 | Ambrx Inc | Modified bovine somatotropin polypeptides and their uses |
| JP2013515081A (ja) | 2009-12-21 | 2013-05-02 | アンブルックス，インコーポレイテッド | 修飾されているブタのソマトトロピンポリペプチドおよびそれらの使用 |
| MX348420B (es) | 2010-07-20 | 2017-06-12 | Halozyme Inc | Efectos secundarios adversos asociados con la administracion de agentes anti-hialuronano y metodos para mejorar o prevenir los efectos secundarios. |
| US9567386B2 (en) | 2010-08-17 | 2017-02-14 | Ambrx, Inc. | Therapeutic uses of modified relaxin polypeptides |
| MA34521B1 (fr) | 2010-08-17 | 2013-09-02 | Ambrx Inc | Polypeptides de relaxine modifiés et leurs utilisations |
| TWI480288B (zh) | 2010-09-23 | 2015-04-11 | Lilly Co Eli | 牛顆粒細胞群落刺激因子及其變體之調配物 |
| ES2630031T3 (es) | 2010-09-28 | 2017-08-17 | Aegerion Pharmaceuticals, Inc. | Un polipéptido de leptina pinnípedo-humano quimérico con solubilidad aumentada |
| AU2012210624A1 (en) * | 2011-01-26 | 2013-07-11 | Novo Nordisk A/S | Leptin derivatives |
| EP2907504B1 (en) | 2011-02-08 | 2017-06-28 | Halozyme, Inc. | Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia |
| WO2012118778A1 (en) | 2011-02-28 | 2012-09-07 | Sanford-Burnham Medical Research Institute | Truncated car peptides and methods and compositions using truncated car peptides |
| AU2012229336B2 (en) * | 2011-03-11 | 2017-02-02 | Genzyme Corporation | Pegylated Apelin and uses thereof |
| US9140698B2 (en) | 2011-04-06 | 2015-09-22 | The Board Of Regents Of The University Of Texas System | Modulating bacterial MAM polypeptides in pathogenic disease |
| EP2715291A4 (en) | 2011-05-31 | 2015-10-21 | Airware Inc | RECALIBRATION OF AB-NDIR GAS SENSORS |
| JP5890516B2 (ja) | 2011-06-17 | 2016-03-22 | ハロザイム インコーポレイテッド | ヒアルロナン分解酵素を用いる連続的皮下インスリン注入方法 |
| US9993529B2 (en) | 2011-06-17 | 2018-06-12 | Halozyme, Inc. | Stable formulations of a hyaluronan-degrading enzyme |
| WO2013026015A1 (en) | 2011-08-18 | 2013-02-21 | Dana-Farber Cancer Institute, Inc. | Muc1 ligand traps for use in treating cancers |
| US10179801B2 (en) | 2011-08-26 | 2019-01-15 | Sanford-Burnham Medical Research Institute | Truncated LYP-1 peptides and methods and compositions using truncated LYP-1 peptides |
| WO2013040501A1 (en) | 2011-09-16 | 2013-03-21 | Pharmathene, Inc. | Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and uses thereof |
| AU2012328880B2 (en) | 2011-10-24 | 2017-02-23 | Halozyme, Inc. | Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof |
| US9243037B2 (en) | 2011-11-10 | 2016-01-26 | Trustees Of Boston College | Gramicidin a mutants that function as antibiotics with improved solubility and reduced toxicity |
| EP3130347B1 (en) | 2011-12-30 | 2019-09-18 | Halozyme, Inc. | Ph20 polypeptide variants, formulations and uses thereof |
| WO2013138730A1 (en) * | 2012-03-16 | 2013-09-19 | Enzon Pharmaceuticals, Inc. | Polymeric conjugates of c1-inhibitors |
| HRP20181187T1 (hr) | 2012-04-04 | 2018-09-21 | Halozyme, Inc. | Kombinirana terapija s hijaluronidazom i taksanom koji ciljano djeluje na tumor |
| PL2859017T3 (pl) | 2012-06-08 | 2019-07-31 | Sutro Biopharma, Inc. | Przeciwciała zawierające swoiste dla miejsca, niewystępujące naturalnie reszty aminokwasowe, sposoby ich wytwarzania i sposoby ich zastosowania |
| WO2014004639A1 (en) | 2012-06-26 | 2014-01-03 | Sutro Biopharma, Inc. | Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use |
| HRP20220455T1 (hr) | 2012-08-31 | 2022-05-27 | Sutro Biopharma, Inc. | Modificirane aminokiseline koje sadrže azid grupu |
| RU2650646C2 (ru) | 2012-09-27 | 2018-04-16 | Дзе Чилдрен'З Медикал Сентер Корпорейшн | Соединения, предназначенные для лечения ожирения, и способы их применения |
| WO2014062856A1 (en) | 2012-10-16 | 2014-04-24 | Halozyme, Inc. | Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods |
| US9789156B2 (en) | 2013-03-11 | 2017-10-17 | Dana-Farber Cancer Institute, Inc. | Combination anti-human epidermal growth factor receptor 2 (anti-HER2) cancer therapy using mucin 1 (MUC1) peptides and hemotherapeutics |
| TW201534726A (zh) | 2013-07-03 | 2015-09-16 | Halozyme Inc | 熱穩定ｐｈ２０玻尿酸酶變異體及其用途 |
| ES2865473T3 (es) | 2013-07-10 | 2021-10-15 | Sutro Biopharma Inc | Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso |
| EP3055298B1 (en) | 2013-10-11 | 2020-04-29 | Sutro Biopharma, Inc. | Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use |
| SI3074033T1 (sl) | 2013-11-26 | 2019-03-29 | The Children's Medical Center Corporation | Spojine za zdravljenje debelosti in postopki njihove uporabe |
| US20170209408A1 (en) | 2014-04-03 | 2017-07-27 | The Children's Medical Center Corporation | Hsp90 inhibitors for the treatment of obesity and methods of use thereof |
| HRP20190881T1 (hr) | 2014-08-28 | 2019-07-12 | Halozyme, Inc. | Kombinacijska terapija s hijaluronan-razgrađujućim enzimom i inhibitorom imunološke kontrolne točke |
| ES2753391T3 (es) | 2014-10-14 | 2020-04-08 | Halozyme Inc | Composiciones de adenosina desaminasa 2 (ADA2), variantes de la misma y métodos de uso de las mismas |
| SMT202100388T1 (it) | 2014-10-24 | 2021-09-14 | Bristol Myers Squibb Co | Polipeptidi fgf-21 modificati e loro usi |
| CA3036551A1 (en) | 2016-09-12 | 2018-03-15 | Aegerion Pharmaceuticals, Inc. | Methods of detecting anti-leptin neutralizing antibodies |
| CN110637027B (zh) | 2017-02-08 | 2024-08-30 | 百时美施贵宝公司 | 包含药代动力学增强子的修饰的松弛素多肽及其用途 |
| SG10202110492YA (en) | 2017-06-22 | 2021-11-29 | Catalyst Biosciences Inc | Modified membrane type serine protease 1 (mtsp-1) polypeptides and methods of use |
| US20190351031A1 (en) | 2018-05-16 | 2019-11-21 | Halozyme, Inc. | Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20 |
| HRP20240016T1 (hr) | 2018-09-11 | 2024-03-29 | Ambrx, Inc. | Konjugati polipeptida interleukina-2 i njihove uporabe |
| WO2020082057A1 (en) | 2018-10-19 | 2020-04-23 | Ambrx, Inc. | Interleukin-10 polypeptide conjugates, dimers thereof, and their uses |
| US11613744B2 (en) | 2018-12-28 | 2023-03-28 | Vertex Pharmaceuticals Incorporated | Modified urokinase-type plasminogen activator polypeptides and methods of use |
| CA3176021A1 (en) | 2018-12-28 | 2020-07-02 | Catalyst Biosciences, Inc. | Modified urokinase-type plasminogen activator polypeptides and methods of use |
| JP7695885B2 (ja) | 2019-02-12 | 2025-06-19 | アンブルックス，インコーポレイテッド | 抗体－ｔｌｒアゴニストコンジュゲートを含有する組成物、その方法、及び使用 |
| WO2021038296A2 (en) | 2019-08-27 | 2021-03-04 | Tonix Pharma Holdings Limited | Modified tff2 polypeptides |
| WO2021183832A1 (en) | 2020-03-11 | 2021-09-16 | Ambrx, Inc. | Interleukin-2 polypeptide conjugates and methods of use thereof |
| EP4199968A1 (en) | 2020-08-20 | 2023-06-28 | Ambrx, Inc. | Antibody-tlr agonist conjugates, methods and uses thereof |
| US20250161471A1 (en) | 2021-04-03 | 2025-05-22 | Feng Tian | Anti-her2 antibody-drug conjugates and uses thereof |
| WO2025227129A2 (en) | 2024-04-25 | 2025-10-30 | Starrock Pharma Llc | Delivery vehicles comprising proglucagon derived polypeptides and anabolic polypeptides and uses thereof |
| WO2025230756A1 (en) | 2024-05-01 | 2025-11-06 | BioLegend, Inc. | Compositions for use with multiple fluorophores and methods of using |
| WO2025250943A1 (en) * | 2024-05-30 | 2025-12-04 | Penguin Bio Corp. | Leptin variants and methods of use thereof |
| WO2026043823A2 (en) | 2024-08-19 | 2026-02-26 | Sutro Biopharma, Inc. | Antibodies comprising site-specific non-natural amino acid residues, methods of preparation and uses thereof |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4002531A (en) | 1976-01-22 | 1977-01-11 | Pierce Chemical Company | Modifying enzymes with polyethylene glycol and product produced thereby |
| US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
| KR850004274A (ko) | 1983-12-13 | 1985-07-11 | 원본미기재 | 에리트로포이에틴의 제조방법 |
| US4703008A (en) | 1983-12-13 | 1987-10-27 | Kiren-Amgen, Inc. | DNA sequences encoding erythropoietin |
| NZ210501A (en) | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
| US4695463A (en) | 1985-05-24 | 1987-09-22 | Warner-Lambert Company | Delivery system for active ingredients and preparation thereof |
| US4766106A (en) * | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| JPS63500636A (ja) | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ |
| US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| US4904584A (en) | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
| US5075222A (en) | 1988-05-27 | 1991-12-24 | Synergen, Inc. | Interleukin-1 inhibitors |
| US5166322A (en) * | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
| RU2212411C2 (ru) | 1989-10-16 | 2003-09-20 | Эмджен Инк. | Полипептид, обладающий гемопоэтической биологической активностью фактора стволовых клеток (варианты), днк (варианты), экспрессирующий вектор (варианты), фармацевтическая композиция для гемопоэтической терапии, способ получения полипептида и способ его использования (варианты) |
| US5372808A (en) | 1990-10-17 | 1994-12-13 | Amgen Inc. | Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect |
| DK0578774T3 (da) | 1991-04-05 | 1999-04-26 | Univ Washington | Monoklonale antistoffer mod stamcellefaktor-receptorer |
| NZ244778A (en) | 1991-10-21 | 1994-03-25 | Ortho Pharma Corp | Peg imidates and protein derivatives thereof |
| US5581476A (en) | 1993-01-28 | 1996-12-03 | Amgen Inc. | Computer-based methods and articles of manufacture for preparing G-CSF analogs |
| US6288030B1 (en) | 1993-12-22 | 2001-09-11 | Amgen Inc. | Stem cell factor formulations and methods |
| US6048837A (en) * | 1994-08-17 | 2000-04-11 | The Rockefeller University | OB polypeptides as modulators of body weight |
| US6001968A (en) * | 1994-08-17 | 1999-12-14 | The Rockefeller University | OB polypeptides, modified forms and compositions |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| US5827734A (en) | 1995-01-20 | 1998-10-27 | University Of Washington | Materials and methods for determining ob protein in a biological sample |
| US5563243A (en) | 1995-01-31 | 1996-10-08 | Eli Lilly And Company | Anti-obesity proteins |
| US5574133A (en) | 1995-01-31 | 1996-11-12 | Eli Lilly And Company | Anti-obesity proteins |
| US5563245A (en) | 1995-01-31 | 1996-10-08 | Eli Lilly And Company | Anti-obesity proteins |
| US5691309A (en) | 1995-01-31 | 1997-11-25 | Eli Lilly And Company | Anti-obesity proteins |
| US5605886A (en) | 1995-01-31 | 1997-02-25 | Eli Lilly And Company | Anti-obesity proteins |
| US5594104A (en) | 1995-01-31 | 1997-01-14 | Eli Lilly And Company | Anti-obesity proteins |
| US5525705A (en) | 1995-01-31 | 1996-06-11 | Eli Lilly And Company | Anti-obesity proteins |
| US5559208A (en) | 1995-01-31 | 1996-09-24 | Eli Lilly And Company | Anti-obesity proteins |
| US5532336A (en) | 1995-01-31 | 1996-07-02 | Eli Lilly And Company | Anti-obesity proteins |
| US5580954A (en) | 1995-01-31 | 1996-12-03 | Eli Lilly And Company | Anti-obesity proteins |
| US5563244A (en) | 1995-01-31 | 1996-10-08 | Eli Lilly And Company | Anti-obesity proteins |
| AU4766596A (en) | 1995-01-31 | 1996-08-21 | Eli Lilly And Company | Ob gene product antibodies |
| US5552523A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
| US5521283A (en) | 1995-01-31 | 1996-05-28 | Eli Lilly And Company | Anti-obesity proteins |
| US5569744A (en) | 1995-01-31 | 1996-10-29 | Eli Lilly And Company | Anti-obesity proteins |
| US5552522A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
| CA2211656A1 (en) | 1995-01-31 | 1996-08-08 | Margret B. Basinski | Anti-obesity proteins |
| US5569743A (en) | 1995-01-31 | 1996-10-29 | Eli Lilly And Company | Anti-obesity proteins |
| US5567803A (en) | 1995-01-31 | 1996-10-22 | Eli Lilly And Company | Anti-obesity proteins |
| JPH10513450A (ja) | 1995-01-31 | 1998-12-22 | イーライ・リリー・アンド・カンパニー | 抗肥満症タンパク質 |
| US5552524A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
| US5554727A (en) | 1995-01-31 | 1996-09-10 | Eli Lilly And Company | Anti-obesity proteins |
| US5567678A (en) | 1995-01-31 | 1996-10-22 | Eli Lilly And Company | Anti-obesity proteins |
| US5594101A (en) | 1995-03-03 | 1997-01-14 | Eli Lilly And Company | Anti-obesity proteins |
| US5719266A (en) | 1995-03-17 | 1998-02-17 | Eli Lilly And Company | Anti-obesity proteins |
| EP0736599A3 (en) | 1995-04-03 | 1996-12-11 | Takeda Chemical Industries Ltd | The rat obesity gene, its gene product and its production |
| WO1996031526A1 (en) | 1995-04-06 | 1996-10-10 | Amylin Pharmaceuticals, Inc. | Anti-obesity agents |
| US5614379A (en) | 1995-04-26 | 1997-03-25 | Eli Lilly And Company | Process for preparing anti-obesity protein |
| DE741187T1 (de) * | 1995-05-05 | 1997-04-30 | Hoffmann La Roche | Rekombinante Obesitäts-(OB)-Proteine |
| GB9509164D0 (en) | 1995-05-05 | 1995-06-28 | Smithkline Beecham Plc | Novel compounds |
| CA2218529A1 (en) | 1995-05-08 | 1996-11-14 | Chiron Corporation | Nucleic acids for treating obesity |
| WO1996037517A1 (en) | 1995-05-26 | 1996-11-28 | Eli Lilly And Company | Rhesus ob protein and dna |
| AU6028396A (en) | 1995-06-07 | 1996-12-30 | Amgen, Inc. | Ob protein compositions and method |
| US5581005A (en) | 1995-06-16 | 1996-12-03 | The Procter & Gamble Company | Method for manufacturing cobalt catalysts |
| CA2224867A1 (en) | 1995-06-22 | 1997-01-09 | Eli Lilly And Company | Obesity protein intermediates and their preparation and use |
| GB2302559B (en) | 1995-06-23 | 1998-06-03 | Draftex Ind Ltd | Opening arrangements and methods for closure members |
| AU6242096A (en) | 1995-06-27 | 1997-01-30 | Takeda Chemical Industries Ltd. | Method of producing sustained-release preparation |
| AU6688896A (en) | 1995-08-17 | 1997-03-12 | Amgen, Inc. | Methods of reducing or maintaining reduced levels of blood lipids using ob protein compositions |
| WO1997016550A1 (en) | 1995-11-02 | 1997-05-09 | Bristol-Myers Squibb Company | Polypeptide fragments derived from the obese gene product |
| WO1997018833A1 (en) | 1995-11-22 | 1997-05-29 | Amgen Inc. | Methods of increasing lean tissue mass using ob protein compositions |
| WO1997020933A2 (en) | 1995-12-06 | 1997-06-12 | Schering Corporation | MUTATIONAL VARIANTS OF MAMMALIAN Ob GENE PROTEINS |
| US6369027B1 (en) | 1995-12-22 | 2002-04-09 | Amgen Inc. | Osteoprotegerin |
| AU1520097A (en) * | 1995-12-27 | 1997-07-28 | Genentech Inc. | Ob protein derivatives having prolonged half-life |
| AU2670897A (en) | 1996-04-04 | 1997-10-29 | Amgen, Inc. | Fibulin pharmaceutical compositions and related methods |
| US6025324A (en) * | 1996-05-15 | 2000-02-15 | Hoffmann-La Roche Inc. | Pegylated obese (ob) protein compositions |
| EP0912609A2 (en) | 1996-06-06 | 1999-05-06 | Smithkline Beecham Plc | Fragments of leptin (ob protein) |
| JP2001501177A (ja) | 1996-08-30 | 2001-01-30 | アムジエン・インコーポレーテツド | Ｏｂタンパク質受容体をアップレギュレートすることによりｏｂタンパク質に対する個体の感受性を増加させる方法 |
| WO1998016545A1 (en) | 1996-10-11 | 1998-04-23 | Eli Lilly And Company | Therapeutic proteins |
| WO1998024896A2 (en) | 1996-12-06 | 1998-06-11 | F. Hoffmann-La Roche Ag | Muteins of obese protein |
| WO1998028427A1 (en) | 1996-12-20 | 1998-07-02 | Amgen Inc. | Ob fusion protein compositions and methods |
| JP4199421B2 (ja) | 1998-08-10 | 2008-12-17 | アムジエン・インコーポレーテツド | デキストラン−レプチン結合体、医薬組成物および関連方法 |
-
1998
- 1998-10-14 US US09/172,644 patent/US6420339B1/en not_active Expired - Lifetime
-
1999
- 1999-10-13 EP EP99970331A patent/EP1121155B1/en not_active Expired - Lifetime
- 1999-10-13 AT AT99970331T patent/ATE463260T1/de not_active IP Right Cessation
- 1999-10-13 DE DE69942231T patent/DE69942231D1/de not_active Expired - Lifetime
- 1999-10-13 JP JP2000575546A patent/JP4854851B2/ja not_active Expired - Lifetime
- 1999-10-13 WO PCT/US1999/024401 patent/WO2000021574A2/en not_active Ceased
- 1999-10-13 CA CA2345027A patent/CA2345027C/en not_active Expired - Lifetime
- 1999-10-13 AU AU14475/00A patent/AU757860B2/en not_active Expired
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002527052A5 (https=) | ||
| CA2345027A1 (en) | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility | |
| AU683121B2 (en) | Compounds with growth hormone releasing properties | |
| WO2002047715A3 (en) | Compositions of peptide crystals | |
| JP2002513556A5 (https=) | ||
| EP2145897A3 (en) | Therapeutic methods and compositions based on serrate proteins and nucleic acids | |
| JP2003510366A5 (https=) | ||
| CY1107051T1 (el) | Αντι-διηθητικα και αντι-αγγειογενετικα θραυσματα ουροκινασης και η χρηση τους | |
| CA2102208A1 (en) | Binding domains in notch and delta proteins | |
| EP1693382A3 (en) | Melanocortin 1 receptor selective compounds | |
| AU9174398A (en) | Peptides | |
| CA2365533A1 (en) | Diagnosis and treatment of neuroectodermal tumors | |
| WO1997009343A3 (fr) | Antagonistes de l'activite oncogenique de la proteine mdm2, et leur utilisation dans le traitement des cancers | |
| WO2001009163A3 (en) | Improvement of peptide transport by conjugation with bile acids | |
| JP2006506097A5 (https=) | ||
| JP2006506942A5 (https=) | ||
| AU2002330289A1 (en) | Preparation of a therapeutic composition | |
| JP2002516284A5 (https=) | ||
| JP2002522512A5 (https=) | ||
| JP2002532067A5 (https=) | ||
| CA2311648A1 (en) | Ifnar2/ifn complex | |
| WO2002058589A3 (en) | Agents and methods for promoting bone growth | |
| JP2002513802A5 (https=) | ||
| RU2004104335A (ru) | Биологически активные пептиды | |
| JP2002518346A5 (https=) |